Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
1,667
Views
0
CrossRef citations to date
0
Altmetric
Dermatology

A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States

D. Willemsa Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8263-4047
ORCID Icon,
C. J. Sayedb Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
,
H. H. Van der Zeec Department of Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands
,
J. R. Ingramd Division of Infection and Immunity, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK
,
E.-L. Hinzpetera Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
,
C. Beaudarta Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands;e Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, BelgiumORCID Iconhttps://orcid.org/0000-0002-0827-5303
ORCID Icon,
S. M. A. A. Eversa Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands;f Trimbos Institute Netherlands Institute of Mental Health and Addiction, Utrecht, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-1026-570X
ORCID Icon &
M. Hiligsmanna Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-4274-9258
ORCID Icon show all
Pages 503-508 | Received 06 Mar 2023, Accepted 21 Mar 2023, Published online: 03 Apr 2023

References

  • Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(13):6709.
  • Garg A, Naik HB, Alavi A, et al. Real-World findings on the characteristics and treatment exposures of patients with hidradenitis suppurativa from US claims data. Dermatol Ther. 2022;13(2):581–594.
  • Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91–101.
  • Ingram JR, Bettoli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597–1605.
  • Kjaersgaard Andersen R, Loft IC, Hansen T, et al. Incidence and remission rates of self-reported hidradenitis suppurativa – A prospective cohort study conducted inandom blood donors. J Eur Acad Dermatol Venereol. 2022;36:717–725.
  • Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo controlled, multicenter studies. Presented at Late-breaking Research Session 1 of the Annual Academy of Dermatology Annual Meeting. March 17-21, 2023; New Orleans, LA.
  • Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, 15 andomized, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761.
  • Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–148.
  • Gaspar K, Hunor Gergely L, Jenei B, et al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2021;22:399–408.
  • Ho MP, Gonzalez JM, Lerner HP, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29:2984–2993.
  • Whichello C, Levitan B, Juhaeri J, et al. Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. BMC Med Inform Decis Mak. 2020;20:114.
  • Willems D, Hinzpeter EL, Van der Zee HH, et al. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. Patient. 2023;16(2):153–164.
  • Kirby JS, Thorlacius L, Villumsen B, et al. The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183:340–348.
  • Willems D, Hiligsmann M, van der Zee HH, et al. Identifying unmet care needs and important treatment attributes in the management of hidradenitis suppurativa: a qualitative interview study. Patient. 2022;15:207–218.
  • Zouboulis CC, Gulliver W, Ingram J, et al. Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round-table session. Exp Dermatol. 2020;29(Suppl 1):67–72.
  • Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179:642–650.
  • Ring HC, Maul JT, Yao Y, et al. Drug survival of biologics in patients with hidradenitis suppurativa. JAMA Dermatol. 2022;158(2):184–188.
  • Overton PM, Shalet N, Somers F, et al. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence. 2021;15:811–834.
  • Faverio K, Peitsch WK, Gorig T, et al. Patient preferences in hidradenitis suppurativa (APProach-HS): a discrete choice experiment. J Dtsch Dermatol Ges. 2022;20:1441–1452.
  • Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403–413.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.